NeuroMetrix NURO 深 滬
等待開盤 10-06 09:30:00 美东时间
4.58
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 4.58
- 總市值 943.34万
- 52周最高 4.73
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.66
- 委 比 0.00%
- 總股本 205.97万
- 歷史最高 10880.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2.66
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NeuroOne Medical Technologies Corporation will participate in the Sidoti & Co. Virtual Small-Cap Conference on September 17-18, 2025. CEO Dave Rosa and CFO Ron McClurg will present on September 17 at 12:15pm ET and host investor meetings. The company reported a 105% revenue increase to $1.7 million in Q3 2025 and a 53.9% gross margin, along with FDA clearance for its OneRF® system. NeuroOne aims to raise investor awareness and discuss growth oppo...
09-08 20:05
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
NeuroNOS, a subsidiary of Beyond Air, announced that the FDA has granted Orphan Drug Designation to its lead therapy, BA-101, for treating Glioblastoma (GBM), a highly aggressive brain tumor with poor prognosis. Despite current treatments, median survival is less than 12 months, with few advancements in decades. Amir Avniel, NeuroNOS' CEO, highlighted the company's commitment to addressing rare neurological conditions and entering oncology. The d...
09-08 12:00
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics Inc. announced that its CEO, Spyros Papapetropoulos, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. The presentation will be available online starting September 5. Neuphoria, a clinical-stage biotech company, is developing therapies for neuropsychiatric disorders, including its lead drug candidate, BNC-210, for the treatment of social anxiety disorder and P...
08-28 20:05
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies Corporation received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, enabling minimally invasive treatment of trigeminal neuralgia, a chronic pain condition affecting around 150,000 people annually. The system uses targeted radiofrequency energy to ablate trigeminal nerve fibers, offering a safer, more precise alternative to traditional pharmaceutical and surgical treatments. NeuroOne plans a limited c...
08-18 12:30
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
Neuronetics, Inc. announced that its CEO, Keith Sullivan, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The presentation will be available to attendees for 14 days post-event. Neuronetics specializes in neurohealth therapies, with NeuroStar Advanced Therapy as its flagship product, offering non-drug treatment for mental health conditions. Its Greenbrook centers have delivered over 7.4 million treatments f...
08-04 20:30
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
NeuroOne Medical Technologies Corporation will release its Q3 2025 financial results on August 14, 2025, before market open. A conference call and webcast will be held at 8:30 a.m. Eastern time on the same day to discuss the results. Participants can join via phone or webcast using the provided details. A replay will be available until August 28, 2025. The company specializes in minimally invasive and high-definition solutions for neurological di...
07-31 12:30
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne Medical Technologies Corporation has received a notice of allowance for a strategic U.S. patent application focused on novel methods for making neural probe devices. This patent covers electrode material deposition, enhancing the functionality and profile of their electrodes. With this addition, their portfolio includes 17 issued and pending patents on thin-film electrode technologies. The Company aims to advance its technology platform ...
07-23 12:30
NeuroPace Announces Strategic CFO Transition
NeuroPace, Inc. appoints Patrick F. Williams as Chief Financial Officer, replacing Rebecca Kuhn, who will transition to an advisory role. Williams, with over 25 years of experience in medical device companies, brings expertise in scaling and growth. He will help expand access to the RNS System, a brain-responsive therapy for epilepsy patients. NeuroPace aims to enhance patient outcomes and advance its mission with Williams' leadership.
06-24 20:05
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Medical Technologies announced that Clara, a patient treated with their OneRF® Ablation System, has remained seizure-free for over a year. Clara, who previously experienced up to 10 seizures daily, has seen a significant improvement in her quality of life since the procedure in June 2024. The OneRF® System, which is FDA-cleared, uses the same sEEG electrode for both diagnosis and therapy, allowing ablation to be performed at the patient’...
06-23 12:30
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. announced the granting of inducement awards, including PRSUs and RSUs, to Jeff Jones, a new non-executive employee. The PRSU awards are tied to achieving cash flow breakeven in specific fiscal quarters, with different vesting schedules based on performance. The RSUs will vest in three equal installments over three years. Neuronetics focuses on neurohealth treatments, offering non-drug therapies and SPRAVATO® for depression.
06-19 23:00
